High-Dose Interleukin-2 (HD IL-2) Therapy Should Be Considered for Treatment of Patients with Melanoma Brain Metastases
Open Access
- 13 May 2013
- journal article
- research article
- Published by Wiley in Chemotherapy Research and Practice
- Vol. 2013, 1-7
Abstract
A retrospective review was performed on patients with stable melanoma brain metastases treated with HD IL-2 therapy (720,000 IU/kg per dose intravenously; 14 doses, 2 cycles per course, maximum 2 courses) from January 1999 to June 2011 at Saint Louis University. There were 5 men and 3 women; median age was 52.2 years (26.8–61.1 years). One patient started treatment with lung lesions only (after resection of melanoma brain disease) and experienced partial response. Seven patients had brain metastases at treatment initiation. Median overall survival (mOS) for entire cohort () was 8.7 months (2.1 to 19.0 months). All patients with brain metastases at first dose () showed progressive disease; mOS was 6.7 months (range 2.1–18.2 months) for this group. Patients received radiosurgery and whole brain radiation before and after HD IL-2 therapy. One patient had symptoms suggestive of neurotoxicity. A history of alcohol abuse was revealed during admission. The patient's symptoms improved with initiation of an alcohol withdrawal protocol. In this analysis, patients with melanoma brain metastases received HD IL-2 without treatment-related mortality. We think that HD IL-2 should be considered as a treatment option in patients with melanoma brain metastases who are otherwise eligible for therapy.Keywords
This publication has 14 references indexed in Scilit:
- Interleukin 2 in Cancer TherapyCurrent Medicinal Chemistry, 2013
- Melanoma in the brainMelanoma Research, 2012
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trialThe Lancet Oncology, 2012
- Outcome predictors of Gamma Knife surgery for melanoma brain metastasesJournal of Neurosurgery, 2011
- Diagnosis-Specific Prognostic Factors, Indexes, and Treatment Outcomes for Patients With Newly Diagnosed Brain Metastases: A Multi-Institutional Analysis of 4,259 PatientsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases.2009
- Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance SystemJournal of Clinical Oncology, 2004
- Safety and Efficacy of High-Dose Interleukin-2 Therapy in Patients With Brain MetastasesJournal of Immunotherapy, 2002
- Malignant melanoma and central nervous system metastases.Incidence, diagnosis, treatment and survivalCancer, 1978
- Metastatic pattern of malignant melanomaThe American Journal of Surgery, 1978